Navigation Links
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
Date:12/1/2008

believe this class of antivirals holds great promise as a component of future HCV treatment regimens."

About ANA598

Anadys recently initiated patient dosing in a Phase Ib study of ANA598 in HCV patients. In the Phase Ib study, naive genotype 1a and 1b patients are to receive ANA598 over three days at doses of 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid. Ten patients will be enrolled at each dose level, eight receiving active drug and two receiving placebo.

In a Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study, although definitive conclusions regarding product safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. All reported adverse events were classified as mild or moderate, with no apparent dose relationship. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 with a half-life of 24 to 30 hours in the fasted state and 22 hours in the fed state, consistent with the potential for once-daily or twice-daily oral dosing.

Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the FDA, subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In the preclinical program, ANA598 was well tolerated at all doses tested in 28-day GLP toxicology studies. In September, Anadys initiated long-term, chronic toxicology studies of ANA598. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of the
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... (PRWEB) August 01, 2014 Chantel Lee ’15 ... research for 10 40-hour weeks with Dr. Juan Rodriguez, Professor ... diabetic retinopathy, a common diabetic eye disease caused by changes ... "What Chantel and Eli accomplished is quite remarkable,” said Rodriguez. ... a concept when they started, and together carried it to ...
(Date:8/1/2014)... Frederick, MD (PRWEB) August 01, 2014 ... and RFID Solutions provider, today officially announces the ... the prestigious Boji Science Park, Baoshan District in ... RURO Shanghai is under the management of Mr. ... International. , In the past three years, RURO’s ...
(Date:8/1/2014)... 1, 2014 The  PROPEL Center  of the  ... success rate of early-stage life sciences companies in ... awarded 15 grants to help Illinois ... Conference   in Chicago .   ... North America , bringing more than ...
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , that the global market RNA ... to nearly $38.8 billion by 2018, with a five-year ... delivery category, the fastest moving segment of the market, ... field of RNAi therapeutics has shown tremendous growth and ...
Breaking Biology Technology:Two Centenary College Students Tackle Diabetic Retinopathy Research 2RURO Opens Office in Shanghai, China 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3
... 28 Pharmacopeia,(Nasdaq: PCOP ), an innovator ... therapeutics, today announced advancements for two members,of its ... and,Regulatory Affairs, has been promoted to Senior Vice ... S. David Kimball, Ph.D., Senior,Vice President, Chemistry and ...
... DIEGO, Feb. 28 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... a,Phase I study of ANA773, the company,s oral TLR7 ... trial is a safety,and tolerability study designed to identify ... to select the dose and,schedule for Phase II trials., ...
... report in the February 28, 2008, New England Journal ... Newborn Screening Program (NENSP) of the University of Massachusetts ... genetic disease, providing what may be the first demonstration ... , The state of Massachusetts has offered universal ...
Cached Biology Technology:Pharmacopeia Announces Management Team Changes 2Pharmacopeia Announces Management Team Changes 3Pharmacopeia Announces Management Team Changes 4Pharmacopeia Announces Management Team Changes 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
(Date:7/31/2014)... models against the highly infectious and virulent bacterium, ... kills approximately 30,000 Americans annually. The research is published ... , In the study, the vaccine protected the ... by C. difficile , as well as from ... the human disease, after only two immunizations. , ...
(Date:7/31/2014)... has been made to help better identify and treat those ... narrowing and enlarging of medium sized arteries in the body, ... organs causing damage. In a new report appearing in August ... scientists provide evidence that that FMD may not be limited ... a connection to abnormalities of bones and joints, as well ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... and 17 September, in the context of France,s presidency ... GMES 2008, at the Grand Palais. The GMES ... set up to provide services relating to the environment, ... services draw on data - mainly Earth observation data ...
... for oceanic vessels has been impeded by worldwide concerns ... gas emissions that impact the Earth,s climate. A ... examines "Emission Tradeoffs among Alternative Marine Fuels: Total Fuel ... Marine Diesel Oil," in a recent issue of ...
... The 2009 Force Protection Equipment,Demonstration (FPED VII) ... VA, and Marine Corps Base, Quantico, VA, next ... Global War on Terror., The demonstration is ... of commercial off-the-shelf equipment solutions to current,and evolving ...
Cached Biology News:Major European program for the environment under the spotlight in Lille, France 2Fuel emissions from marine vessels remain a global concern 22009 Force Protection Equipment Demonstration Set for Next May 19-21 2
... Acridinium NHS ester can ... and nucleic acids. The covalently ... produce chemiluminescence in the presence ... ester-labeled proteins can be used ...
... 2-color real-time PCR detection system holds 48 x ... array of 48 LEDs independently excites fluorescence (470-500 ... filtered photodiodes detects emitted light (523-543 nm and ... MJ Mini cycler, whose Peltier heat pumps provide ...
... flow cytometry accessible to anyone in the lab. ... addition to Guavas on-demand microcapillary flow cytometry systems ... use, surprisingly affordable, very compact, and nicely equipped ... Guava EasyCyte Mini has all of the functionality ...
... hold up to 6 strain chambers with precise ... use design ensures that cells grow over long ... compression. This unit allows you to control the ... 64 unique strain settings. The instrument fits in ...
Biology Products: